News
Low copays drive better adherence to new diabetes drugs
Regardless of patients’ socioeconmic status, copays were related to adherence.
News
BMI ‘vastly underestimates’ true obesity
“We’re at the start of the end of BMI.”
News
Anabolic-steroid withdrawal regimens show promise in men
“There is a vacuum of medical advice on what to do” when men stop taking steroids.
News
Troponin to ID diabetes patients with silent heart disease?
“What we are seeing is that many people with type 2 diabetes who have not had a heart attack or a history of cardiovascular disease are at high...
News
FDA approves new drug, sotagliflozin, for heart failure
“It will be a reasonably tall task for sotagliflozin to come from behind and be disruptive in a space where there are already two well-established...
News
CKD Screening in all U.S. adults found cost effective
Modeling showed screening for and treating chronic kidney disease in U.S. adults was cost effective now that SGLT2 inhibitors are available.
News
Tirzepatide scores win in second obesity trial, SURMOUNT-2
Tirzepatide (Mounjaro) met its primary endpoints, compared with placebo, in the SURMOUNT-2 trial, designed to test weight-loss efficacy, in top-...
News
BMI is a flawed measure of obesity. What are alternatives?
“BMI is trash. Full stop.”
News
‘Unheard of’ PAH improvement with novel drug: STELLAR
Sotatercept, a designer molecule that removes a key driver of pulmonary arterial hypertension, had efficacy and safety in the first of three...
News
Can SGLT2 inhibitors limit acute kidney injury in type 2 diabetes?
Contrary to the initial concerns that SGLT2 inhibitors might increase the risk of acute kidney injury, new data indicate that this complication is...
News
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
Only 9% of eligible adults with T2D received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, in a new analysis.